Drug discovery and development is a complicated and lengthy process, one that necessitates a great deal of financial, labor, and time investment. Yet drug development experiences a high attrition rate, as putative compounds fail to deliver the desired efficacies, or researchers discover that they pose unacceptable risks to human health. ADMET (absorption, distribution, metabolism, elimination, and toxicity) testing characterizes promising pharmacological compounds, identifying both those with potential and those with major disqualifying drawbacks.
Mandy Xu is the Vice President of Drug Metabolism and Pharmacokinetics for Pharmaron, an international contract research organization headquartered in Beijing, China that is dedicated to providing drug research and development services for the life sciences industry. A graduate of Peking University, Xu currently leads a team of more than 200 individuals in providing in vitro ADMET solutions for researchers in the biotech and pharma industries. “My team mainly focuses on early discovery… to determine the activity ...